|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Burden of Clostridium difficile infection between 2010 and 2013:Trends and outcomes from an academic center in Eastern Europe显示文摘AIM:To analyze the incidence and possible risk factors in hospitalized patients treated with Clostridium difficile infection(CDI).METHODS:A total of 11751 patients were admitted to our clinic between 1 January 2010 and 1 May2013.Two hundred and forty-seven inpatients were prospectively diagnosed with CDI.For the risk analysis a 1:3 matching was used.Data of 732 patients matched for age,sex,and inpatient care period and unit were compared to those of the CDI population.Inpatient records were collected from an electronic hospital database and comprehensively reviewed.RESULTS:Incidence of CDI was 21.0/1000 admissions(2.1%of all-cause hospitalizations and 4.45%of total inpatient days).The incidence of severe CDI was 12.6%(2.63/1000 of all-cause hospitalizations).Distribution of CDI cases was different according to the unit type,with highest incidence rates in hematology,gastroenterology and nephrology units(32.9,25 and24.6/1000 admissions,respectively) and lowest rates in 1.4%(33/2312) in endocrinology and general internal medicine(14.2 and 16.9/1000 admissions)units.Recurrence of CDI was 11.3%within 12 wk after discharge.Duration of hospital stay was longer in patients with CDI compared to controls(17.6 ± 10.8d vs 12.4 ± 7.71 d).CDI accounted for 6.3%of allinpatient deaths,and 30-d mortality rate was 21.9%(54/247 cases).Risk factors for CDI were antibiotic therapy[including third-generation cephalosporins or fluoroquinolones,odds ratio(OR) = 4.559;P < 0.001],use of proton pump inhibitors(OR = 2.082,P< 0.001),previous hospitaiization within 12 mo(OR = 3.167,P < 0.001),previous CDI(OR = 15.32;P < 0.001),while presence of diabetes mellitus was associated with a decreased risk for CDI(OR = 0.484;P< 0.001).Treatment of recurrent cases was significantly different from primary infections with more frequent use of vancomycin alone or in combination(P < 0.001),and antibiotic therapy duration was longer(P < 0.02).Severity,mortality and outcome of primary infections and relapsing cases did not significantly differ.CONCLUSION:CDI was accounted for significant burden with longer hospitaiization and adverse outcomes.Antibiotic,PPI therapy and previous hospitaiization or CDI were risk factors for CDI. | Zsuzsanna Kurti Barbara D Lovasz Michael D Mandel Zoltan Csima Petra A Golovics Bence D Csako Anna Mohas Lorant Gnczi Krisztina B Gecse Lajos S Kiss Miklos Szathmari Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，21： | 6 |
| 2 | Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease显示文摘AIM:To investigate intestinal alkaline phosphatase(iAP) in the intestinal mucosa of children with inflammatory bowel disease(IBD).METHODS:Colonic biopsy samples were taken from 15 newly diagnosed IBD patients and from 10 healthy controls.In IBD patients,specimens were obtainedboth from inflamed and non-inflamed areas.The iAP mRNA and protein expression was determined by reverse transcription-polymerase chain reaction and Western blotting analysis,respectively.Tissue localization of iAP and Toll-like receptor(TLR) 4 was investigated by immunofluorescent staining.RESULTS:The iAP protein level in the inflamed mucosa of children with Crohn's disease(CD) and ulcerative colitis(UC) was significantly decreased when compared with controls(both P < 0.05).Similarly,we found a significantly decreased level of iAP protein in the inflamed mucosa in CD compared with non-inflamed mucosa in CD(P < 0.05).In addition,the iAP protein level in inflamed colonic mucosa in patients with UC was decreased compared with non-inflamed mucosa in patients with CD(P < 0.05).iAP protein levels in the non-inflamed mucosa of patients with CD were similar to controls.iAP mRNA expression in inflamed colonic mucosa of children with CD and UC was not significantly different from that in non-inflamed colonic mucosa with CD.Expression of iAP mRNA in patients with noninflamed mucosa and in controls were similar.Co-localization of iAP with TLR4 showed intense staining with a dotted-like pattern.iAP was present in the inflamed and non-inflamed mucosa of patients with CD,UC,and in control biopsy specimens,irrespective of whether it was present in the terminal ileum or in the colon.However,the fluorescent signal of TLR4 was more pronounced in the colon compared with the terminal ileum in all groups studied.CONCLUSION:Lower than normal iAP protein levels in inflamed mucosa of IBD patients may indicate a role for iAP in inflammatory lesions in IBD.Based on our results,administration of exogenous iAP enzyme to patients with the active form of IBD may be a therapeutic option. | Kriszta Molnár dám Vannay Beáta Szebeni Nóra Fanni Bánki Erna Sziksz ron Cseh Hajnalka Gyrffy Péter László Lakatos Mária Papp András Arató Gábor Veres | 2012 | World Journal of Gastroenterology2012，18，25： | 5 |
| 3 | Biological therapy in inflammatory bowel diseases:Access in Central and Eastern Europe显示文摘Biological drugs opened up new horizons in the management of inflammatory bowel diseases(IBD).This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European(CEE)countries,namely Bulgaria,the Czech Republic,Estonia,Hungary,Latvia,Lithuania,Poland,Romania and Slovakia.Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed.Moreover,we provide an estimation on prevalence of IBD as well as biological treatment rates.In all countries with the exception of Romania,lower biological treatment rates were observed in ulcerative colitis(UC)compared to Crohn’s disease despite the higher prevalence of UC.Great heterogeneity(up to 96-fold)was found in access to biologicals across the CEE countries.Poland,Bulgaria,Romania and the Baltic States are lagging behind Hungary,Slovakia and the Czech Republic in their access to biologicals.Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria,Latvia,Lithuania,and Poland,but association with other possible determinants(differences in prevalence and incidence,price of biologicals,total expenditure on health,geographical access,and cost-effectiveness results)was not proven.We assume,nevertheless,that healthdeterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD.In conclusion,access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors,drug prices or total health expenditure.Changes in reimbursement policy could contribute to better access to biologicals in some countries. | Fanni Rencz Márta Péntek Martin Bortlik Edyta Zagorowicz Tibor Hlavaty Andrzej Sliwczyński Mihai M Diculescu Limas Kupcinskas Krisztina B Gecse László Gulácsi Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，6： | 4 |
| 4 | Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy显示文摘AIM:To assess the endoscopic activity before and after a one-year period of biological therapy and to evaluate the frequency of relapses and need for retreatment after stopping the biologicals in patients with Crohn’s disease(CD)and ulcerative colitis(UC).METHODS:The data from 41 patients with CD and 22 patients with UC were assessed.Twenty-four CD patients received infliximab,and 17 received adalimumab.The endoscopic severity of CD was quantified with the simplified endoscopic activity score for Crohn’s disease in CD and with the Mayo endoscopic subscore in UC.RESULTS:Mucosal healing was achieved in 23 CD and7 UC patients.Biological therapy had to be restarted in78%of patients achieving complete mucosal healing with CD and in 100%of patients with UC.Neither clinical remission nor mucosal healing was associated with the time to restarting the biological therapy in either CD or UC.CONCLUSION:Mucosal healing did not predict sustained clinical remission in patients in whom the biological therapies had been stopped. | Klaudia Farkas Péter László Lakatos Mónika Szcs va Pallagi-Kunstár Anita Bálint Ferenc Nagy Zoltán Szepes Noémi Vass Lajos S Kiss Tibor Wittmann Tamás Molnár | 2014 | World Journal of Gastroenterology2014，20，11： | 2 |
| 5 | Response of asym metric dimethylarginine to hemodialysis associated hy- potension in end stage renal disease patient显示文摘 | Csiky B Sulyok E Lakatos O | 2008 | Neph- ron Clin Pract2008，108，： | 1 |
| 6 | Low temperature in-hibits RNA silencing -mediated defence by the control of siRNAgeneration显示文摘 | SZITTYA G SILHAVY D MOLNAR A HAVELDA Z LOVAS A LAKATOS L BANFALVI Z B'URGYAN J | 2003 | EMBO J2003，22，： | 1 |
| 7 | Involvement of sphingosinein dexamethasone-induced thymocyte apoptosis显示文摘 | Lepine S Lakatos B Maziere P | 2002 | Ann N Y Acad Sci2002，973，： | 1 |
| 8 | Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function显示文摘 | Bonow R O Lakatos E Maron B J | 1991 | Circulation1991，84，4： | 1 |
| 9 | ATP-induced apoptosis of thymocytes is mediated by activation of 1?2 X 7 receptor and in- volves de novo ceramide synthesis and mitochondria 显示文摘 | Lepine S Le Stunff H Lakatos B | 2006 | Biochim Biophys Acta2006，1761，1： | 1 |
| 10 | Genetic diversity of Hungarian canine distemper virus strains显示文摘 | Demeter Z Lakatos B Palade E A | 2007 | Veterinary Microbiology2007，122，34： | 1 |
| 11 | Genetic diversity of hungarian canine distemper virus strains显示文摘 | DEMETER Z LAKATOS B PALADE E A | 2007 | Vet Microbiol2007，122，34： | 1 |
| 12 | Evaluation of the malnutrition-in-flammation score in kidney transplant recipients显示文摘 | Molnar MZ Keszei A Czira ME Rudas A UjszasziA Haromszeki B Kosa JP Lakatos P Sarvary E Beko G | 2010 | Am J Kidney Dis2010，，： | 1 |
| 13 | Genetic diversity of Hungarian canine distemper virus strains 显示文摘 | Demeter Z Lakatos B Palade E A | 2007 | Vet Microbiol2007，122，34： | 1 |
| 14 | Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients显示文摘 | Csiky B Sulyok E Lakatos O | | 0，，： | 1 |
| 15 | Acute compartment Syndrome of the thigh显示文摘 | Schwartaz JR Brumback RJ lakatos B | 1989 | J Bone joint Surg(Am)1989，71，： | 1 |
| 16 | Predictors of relapse in patients with Crohn’s disease in remission after 1 year of biological therapy显示文摘 | T. Molnár P. L. Lakatos K. Farkas F. Nagy Z. Szepes P. Miheller G. Horváth M. Papp K. Palatka T. Nyári A. Bálint K. L?rinczy T. Wittmann | 2012 | Aliment Pharmacol Ther2012，，2： | 1 |
| 17 | Effect of gypsum on proliferation and differentiation of MC3T3-E1 mouse osteoblastic cells显示文摘 | áron Lazáry Bernadett Balla János P. Kósa Krisztián Bácsi Zsolt Nagy István Takács Péter P. Varga Gábor Speer Péter Lakatos | 2006 | Biomaterials2006，，3： | 1 |
| 18 | Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics显示文摘 | Mandel D. Michael Anita Bálint Barbara D. Lovász László Gulácsi Bálint Strbák Petra A. Golovics Klaudia Farkas Zsuzsanna Kürti Blanka K. Szilágyi Anna Mohás Tamás Molnár Péter L. Lakatos | 2014 | The European Journal of Health Economics2014，，1： | 1 |
| 19 | Silent chorioamnionitis and associated pregnancy outcomes: a review of clinical data gathered over a 16-year period显示文摘 | Horvath B Lakatos F T6th C | 2014 | J Perinat Med2014，42，4： | 1 |
| 20 | Investigation and simulation of crystallization of high aspect ratio crystals with fragmentation显示文摘 | BORSOS A LAKATOS B G | 2014 | Chemical Engineering Research and Design2014，92，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员